Brian Oscar Bingen

Brian Oscar Bingen

Auto-generated profile, based on publicly available information

Brian Oscar Bingen

Department of Cardiology Leiden University Medical Center Leiden The Netherlands

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 June 2024 in Catheterization and Cardiovascular Interventions
Verified
Journal Article
Open access
MOMartijn J. H. van Oort
Martijn J. H. van Oort
IAIbtihal Al Amri
Ibtihal Al Amri
BBBrian O. Bingen
Brian O. Bingen
FOFederico Oliveri
Federico Oliveri
VVVictoria Vilalta
Victoria Vilalta
JMJose Montero-Cabezas
Jose Montero-Cabezas
Background: Intravascular lithotripsy (IVL) combined with rotational atherectomy (RA), known as Rotatripsy, is used to treat severe coronary artery calcification (CAC), though data on efficacy, midterm safety and use sequence is limited. We aimed to identify indicators for Rotatripsy use and to assess its safety and success rates, both acutely and at 1‐year follow‐up.Methods: Patients undergoing Rotatripsy for severe CAC across six centers from May 2019 to December 2023 were included. Demographic, clinical, procedural and follow‐up data were collected. Efficacy endpoints included device success (delivery of the RA‐burr and IVL‐balloon across the target lesion and administration of therapy without related complications), technical success (TIMI 3 flow and residual stenosis <30% by quantitative coronary analysis) and procedural success [composite of technical success with absence of in‐hospital major adverse cardiovascular events (MACE: cardiac death, myocardial infarction or target vessel revascularization). Safety endpoints comprised Rotatripsy‐related complications and MACE at 1‐year follow‐up.Results: A total of 114 patients (75 ± 9 years, 78% male) underwent Rotatripsy for 120 lesions. In the majority of procedures RA was followed by IVL, mostly electively (n = 68, 57%) but also for balloon underexpansion (n = 37, 31%) and stent crossing failure (n = 1, 1%). Diverse and complex target lesions were addressed with an average SYNTAX score of 24.6 ± 13.0. Device, technical and procedural success were 97%, 94% and 93%, respectively. Therapy‐related complications included two (2%) coronary perforations, one (1%) coronary dissection and one (1%) burr entrapment. At 1‐year follow‐up(present in 77(67%) patients), MACE occurred in 7(9%) cases.Conclusions: Over a 1‐year follow‐up period, Rotatripsy was safe and effective, predominantly using RA electively before IVL.

27 May 2025 in Catheterization and Cardiovascular Interventions
Verified
Journal Article
Open access
APAkshay A. S. Phagu
Akshay A. S. Phagu
MOMartijn J. H. van Oort
Martijn J. H. van Oort
FOFederico Oliveri
Federico Oliveri
BBBrian O. Bingen
Brian O. Bingen
GMGianluca Mincione
Gianluca Mincione
JMJose Montero-Cabezas
Jose Montero-Cabezas
Background: Intravascular lithotripsy (IVL) is an innovative treatment for coronary artery calcification (CAC). Aims: This study aimed to compare procedural and clinical outcomes of intracoronary imaging (ICI)‐guided percutaneous coronary intervention (PCI) versus angiography‐guided PCI with IVL in patients with CAC. Methods: A total of 509 patients were analyzed from the BENELUX‐IVL registry (May 2019 to September 2024). Angiography‐guided PCI with IVL was defined as therapy under solely fluoroscopic guidance. ICI‐guided PCI with IVL was defined as PCI with IVL and concomitant use of ICI for procedural guidance either pre‐ and/or post‐IVL. The primary endpoint was procedural success, defined as Thrombolysis In Myocardial Infarction (TIMI) 3 flow, residual stenosis < 30%, and absence of in‐hospital major adverse cardiovascular events (MACE). Safety endpoints included procedural complications and MACE up to 2‐year follow‐up. Results: A total of 537 lesions were treated with IVL: 252 (46.9%) angiography‐guided and 285 (53.1%) ICI‐guided. The ICI‐guided group had more complex lesions, with higher rates of aorto‐ostial (20.2% vs. 30.9%; p = 0.005), chronic total occlusions (2.8% vs. 12.3%; p = 0.001), and long‐segment lesions (58.7% vs. 69.5%; p = 0.009). Procedural success rates were comparable between groups (88.7% vs. 89.7%; p = 0.71), as were device success (97.9% vs. 97.4%; p = 0.72) and technical success (89.1% vs. 91.5%; p = 0.35). MACE rates remained similar at all time points up to 2‐year follow‐up ( p > 0.05). Conclusion: Procedural success was comparable between angiography‐guided and ICI‐guided PCI with IVL, despite greater lesion complexity in the ICI‐guided group. Complication rates were similar, with no significant differences in MACE or mortality at long‐term follow‐up.

29 August 2024 in Catheterization and Cardiovascular Interventions
Verified
Journal Article
Open access
FOFederico Oliveri
Federico Oliveri
MOMartijn J. H. van Oort
Martijn J. H. van Oort
IAIbtihal Al Amri
Ibtihal Al Amri
BBBrian O. Bingen
Brian O. Bingen
BCBimmer Claessen
Bimmer Claessen
JMJose Montero-Cabezas
Jose Montero-Cabezas
Background: Calcification within chronic total occlusions (CTO) is strongly associated with worse outcomes. Despite the excellent success and safety of intravascular lithotripsy (IVL) in heavily calcified lesions, evidence in CTO remains scarce.Aim: This study aimed to evaluate the procedural and long‐term clinical outcomes of IVL in heavily calcified CTO.Methods: Patients who underwent IVL between 2019 and 2024 from an ongoing prospective multicenter registry were eligible for inclusion. Patients were therefore classified in CTO and non‐CTO groups. The efficacy and safety endpoints of CTO percutaneous coronary interventions were defined according to the CTO‐ARC consensus. In‐hospital major adverse cardiovascular events (MACE) included cardiac death, nonfatal myocardial infarction and target lesion revascularization (TVR).Results: A total of 404 patients underwent IVL, of which the treated lesion was a CTO in 33 (8.2%). The mean J‐CTO score was 2.3 ± 1.1. Device success showed no significant difference between CTO and non‐CTO groups (100% vs 98.4%; p = 0.35). Comparable technical success with residual stenosis <30% was observed in both groups (90.1% in CTO vs 89.2% in non‐CTO, p = 0.83). The incidence of MACE was similar across groups during hospital stays (CTO 6.0% vs. non‐CTO 1.9%, p = 0.12), at 30‐day (CTO 9.1% vs. non‐CTO 3.0%, p = 0.07), and at 12‐month follow‐up (CTO 9.1% vs. non‐CTO 7.3%, p = 0.70).Conclusion: IVL provides high procedural success and consistent clinical outcomes in both CTO and non‐CTO cases, reinforcing its role in managing heavily calcified coronary lesions.

4 July 2025 in eClinicalMedicine
Verified
Journal Article
Open access
FOFederico Oliveri
Federico Oliveri
PGPablo Valentín García
Pablo Valentín García
MOMartijn J.H. van Oort
Martijn J.H. van Oort
APAkshay Phagu
Akshay Phagu
IAIbtihal Al Amri
Ibtihal Al Amri
JMJose Montero-Cabezas
Jose Montero-Cabezas
Patients of advanced age are frequently underrepresented or excluded from major clinical trials, leading to limited evidence in this population and a reliance on data extrapolated from younger populations. The present study aims to compare and evaluate the safety and efficacy of intravascular lithotripsy (IVL) for the treatment of calcified coronary lesions in individuals of advanced age and in younger populations. In this post-hoc analysis, from the ongoing prospective, multicenter BENELUX-IVL registry involving nine hospitals across four countries in the European Union, patients undergoing percutaneous coronary intervention (PCI) with intravascular lithotripsy (IVL) were retrospectively stratified into two groups: advanced age (≥80 years) and younger (<80 years). The primary technical endpoint was technical success, defined as successful IVL catheter crossing of the target lesion with residual stenosis <30%. The primary safety endpoint was in-hospital major adverse cardiac events (MACE). This study is registered with ClinicalTrials.gov, number NCT06577038. Between January 2019 and April 2025, 583 patients underwent PCI with IVL; of these, 147 (25.2%) patients were aged ≥80 years (advanced age cohort), and the remaining 436 (74.8%) were aged <80 years (younger cohort). Compared to younger patients, the advanced age cohort had higher SYNTAX score (23 [IQR 15–32] vs. 18 [IQR 11–28], p = 0.01) and more comorbidities. Intraprocedural complications (severe dissection, abrupt vessel closure, and perforation) were low in both groups, with no significant differences between them. Technical success was comparable between the advanced age and younger populations (87.8% vs. 90.6%, RR: 0.97 (0.91–1.04), p = 0.32). In-hospital MACE rates were similar between the advanced age and younger cohorts (1.4% vs. 2.1%, RR: 0.64 (0.19–2.18), p = 0.59), and these results remained consistent at 1-year follow-up (6.1% vs. 8.0%, RR: 0.76 (0.38–1.55) p = 0.51). In patients of advanced age, IVL for calcified coronary lesions demonstrates a favorable safety and efficacy profile, with high technical success and low rates of device-related adverse events. Nonetheless, larger studies with extended follow-up are warranted to confirm these findings and establish long-term outcomes. This work was funded through a research grant from 10.13039/100031956 Shockwave Medical .

23 June 2025 in Catheterization and Cardiovascular Interventions
Verified
Journal Article
Open access
FOFederico Oliveri
Federico Oliveri
GDGiulia D'ACunto
Giulia D'ACunto
MOMartijn. J.H. van Oort
Martijn. J.H. van Oort
APAkshay Phagu
Akshay Phagu
IAIbtihal Al Amri
Ibtihal Al Amri
JMJose Montero-Cabezas
Jose Montero-Cabezas
Background: Intravascular lithotripsy (IVL) has emerged as a promising treatment for heavily calcified coronary lesions. However, evidence regarding its effectiveness in calcific bifurcation lesions remains limited. Objective: We aimed to evaluate the technical success and 1‐year clinical outcomes of IVL in calcified coronary bifurcation lesions. Methods: Patients undergoing PCI with the use of IVL from the ongoing prospective BENELUX‐IVL registry were included. Participants were stratified into bifurcation and non‐bifurcation groups. The primary technical endpoint was technical success, defined as successful crossing of the IVL catheter across the target lesion with a residual stenosis of < 30%. The primary safety endpoint was in‐hospital major adverse cardiac events (MACE). Results: Among 509 patients, 114 (22.4%) had coronary bifurcation lesions. Compared to the non‐bifurcation group, the bifurcation group had higher SYNTAX scores (25 [18–33] vs. 18 [10–29]; p < 0.01), longer procedural times (100 [75–129] min vs. 78 [59–107] min; p < 0.01), and greater contrast volume use (208 ± 8 mL vs. 176 ± 4 mL; p < 0.01). Abrupt side branch occlusion (1.8%) and bail‐out two‐stent techniques (3.6%) were infrequent. IVL achieved comparable technical success (91.2% vs. 90.0%, p = 0.71) and 1‐year MACE rates (9.6% vs. 5.8%, p = 0.20) in bifurcation versus non‐bifurcation lesions. Conclusion: IVL demonstrates excellent safety and efficacy in calcified coronary bifurcation PCI, achieving high technical success with low device‐dependent adverse event rates.

23 September 2024 in Catheterization and Cardiovascular Interventions
Verified
Journal Article
Open access
FOFederico Oliveri
Federico Oliveri
MMMaura Meijer
Maura Meijer
MOMartijn J. H. Van Oort
Martijn J. H. Van Oort
IAIbtihal Al Amri
Ibtihal Al Amri
BBBrian O. Bingen
Brian O. Bingen
JMJose Montero-Cabezas
Jose Montero-Cabezas
Background: Percutaneous coronary intervention of calcified aorto‐ostial lesions (AOL) pose unique challenges due to anatomical propensity for recoil, leading to poorer outcomes compared to non‐AOL. Although intravascular lithotripsy (IVL) has shown excellent success and safety in heavily calcified plaques, evidence specific to AOL is limited. This study aims to evaluate the efficacy and safety of IVL in AOL versus non‐AOL.Methods: Patients treated with IVL between 2019 and 2023 from an ongoing prospective multicenter registry were eligible for inclusion. Patients were therefore classified in AOL and non‐AOL groups, based on anatomical location. The primary technical endpoint was device success, defined as the ability to deliver the IVL catheter and pulses at the target lesion, without angiographic complications. Secondary technical endpoint encompassed procedural success <30%, consisting of device success with residual stenosis <30%, final thrombolysis in myocardial infarction grade 3 flow, and no in‐hospital major adverse cardiovascular events (MACE). The primary clinical endpoint was in‐hospital MACE, including cardiac death, nonfatal myocardial infarction, or target lesion revascularization.Results: A total of 321 patients underwent IVL, including 48 with AOL. Device success showed no significant difference between AOL and non‐AOL groups (100% vs. 98.2%; p = 0.35). A nonsignificant trend toward worse procedural success with residual stenosis <30% was observed in the AOL arm (AOL 81.3% vs. non‐AOL 90.5%, p = 0.06). In‐hospital MACE was significantly higher in AOL (4.2% vs. 0.7%, p = 0.048), attributed entirely to cardiac deaths. At 6‐month follow‐up, the incidence of MACE (AOL 8.3% vs. non‐AOL 4.0%, p = 0.19), and cardiac deaths (AOL 4.2% vs non‐AOL1.1%, p = 0.11) were comparable between groups.Conclusion: IVL treatment for heavily calcified AOL demonstrates comparable procedural and 6‐month clinical outcomes when compared to non‐AOL, despite a higher incidence of in‐hospital MACE.